BioCentury
ARTICLE | Company News

iPierian, Bristol-Myers deal

May 5, 2014 7:00 AM UTC

Bristol-Myers Squibb acquired neurology play iPierian for $175 million in cash up front and up to $550 million in milestones, plus royalties. iPierian's IPN007 is a preclinical humanized mAb targetin...